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Overview and Epidemiologic Considerations
Acetaminophen (APAP) is a highly effective analgesic and
antipyretic agent that is safely used by millions of people
every day. However, APAP is also a dose-dependent hepato-
toxin that is present in over 600 marketed products and
can cause acute pericentral liver injury when taken in doses
exceeding 6 to 10 grams/day (Table 1). APAP overdose is
the most common cause of drug-induced liver injury in the
United States, with  60,000 cases reported each year, and
also accounts for nearly 50% of adult acute liver failure
(ALF) cases.1 Intentional APAP overdose as a suicide gesture
accounts for a majority of these cases, but there has been a
significant increase in nonintentional APAP overdose cases
over the past 2 decades.2 Overall mortality remains low (<
1%) in intentional APAP overdose patients who receive
NAC promptly. However, nearly 50% of the APAP ALF cases
are attributed to ‘‘therapeutic misadventures’’—patients who
frequently ingest multiple APAP-containing products and
present with more advanced encephalopathy and liver
injury.3 Because there are at least 500 deaths each year in
the United States attributed to APAP overdose, there are
increasing calls for regulatory actions regarding APAP dos-
ing, dispensing, packaging, and coformulation with opioid
analgesics.
Diagnosis and Clinical Presentation
Most patients with APAP overdose have minimal or non-
specific symptoms such as malaise, abdominal pain or nau-
sea, and vomiting at presentation. A detailed medication
history can help ascertain total APAP exposure but can be
challenging in patients with polydrug overdose or advanced
encephalopathy. The Rumack-Matthew nomogram to predict
the likelihood of hepatotoxicity is recommended for initial
assessment of all patients with a single time-point overdose
(Fig. 1).4 Although APAP is rapidly absorbed from the gas-
trointestinal tract, a repeat serum APAP level 4 hours after
initial presentation is advisable to better define the risk of
liver injury. Of note, the serum APAP level may be low or
undetectable in patients who overdose over several days,
and NAC should not be delayed whenever there is any clin-
ical suspicion of APAP overdose. Serum acetaminophen-
protein adducts are covalent adducts of APAP with a much
longer half-life than the parent compound, which can be a
helpful diagnostic tool in ambiguous cases, but this assay is
not commercially available.5
Serum aminotransferase levels are frequently normal
shortly after intentional APAP overdose but may rapidly
increase during the first 24 hours of hospitalization. Some
subjects may present with an isolated metabolic or lactic
acidosis with or without acute kidney injury or an elevation
in their international normalized ratio (INR) (Table 2). All
patients with elevated serum aminotransferase levels should
be evaluated for other etiologies of acute liver injury (ie
hepatitis A, B, C; ischemia; pancreaticobiliary disease), as
well as ingestion of other illicit substances (Table 2). A
rapid assessment of the severity of liver injury is performed
by a combination of clinical (grade of encephalopathy) and
laboratory (liver chemistries, creatinine, INR, arterial PH,
arterial lactate, and factor V assay) parameters. An early
assessment of disease severity can help determine the
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appropriate level of care for a given patient (ie general floor
vs intensive care unit [ICU]). A psychiatric and social work
evaluation of all patients with intentional APAP overdose
should be initiated in parallel with their NAC treatment to
maximize patient safety and avoidance of further harm.
Standard Treatment
All patients who present within 4 hours of APAP overdose
should receive ipecac syrup to induce vomiting—or naso-
gastric lavage to remove pill fragments, followed by acti-
vated charcoal to reduce APAP absorption. NAC, which
repletes the intrahepatic glutathione stores, also should be
administered promptly via oral or intravenous (IV) route
based on the patient’s clinical condition.4 Of note, NAC is a
pungent sulfa drug that can cause significant nausea and
vomiting in 20% to 30% of patients, and IV NAC can lead
to rash and a non-IgE–mediated hypersensitivity reaction.
Recently, a randomized trial has shown better tolerance and
fewer side effects with a 12-hour IV regimen of NAC versus
the standard 20-hour IV regimen, but confirmatory studies
are needed6 (Table 3). The incidence of hepatotoxicity
is< 10% in those receiving NAC within 8 hours of inges-
tion but increases to 40% if NAC is delayed> 16 hours.
The goal of supportive care is to provide the optimal
environment for hepatic recovery, vital organ support, and
prevention and treatment of complications. General sup-
portive measures include volume resuscitation and vaso-
pressor support, monitoring for bleeding complications,
monitoring and treatment of infections, respiratory support,
avoidance of nephrotoxins, and renal support as needed.7
Monitoring and treatment of hypoglycemia and hypophos-
phatemia are also important. Therefore, liver chemistries,
renal function, INR, acid base status, and factor V should
be checked every 12 hours. Subjects with no evidence of
liver injury, coagulopathy, or kidney injury at 24 hours after
presentation may have NAC discontinued and be treated
supportively. In contrast, patients with evidence of early
TABLE 1 Acetaminophen Content of Some Commonly Used OTC
Products
OTC Products
Acetaminophen
Per Dose (mg)
Analgesics/antipyretics
Children’s Tylenol products 80-160 mg, 160 mg/5 ml*
Excedrin products 325-500 mg
Goody’s Extra Strength
powder products
250-500 mg
Goody’s Headache Relief Shot 1000 mg/60 ml*
Midol products 500 mg
Midrin 325 mg
Pamprin products 250 mg
Tylenol Regular Strength 325 mg
Tylenol Extra Strength 500 mg
Tylenol Muscles Aches & Body
pains/Arthritis Pain
650 mg
Cold, cough, and sinus products
Alka-Seltzer products 325 mg
Coricidin HBP Maximum Strength Flu 500 mg
Delsym Cough and Night Time
Cold & Cough
650 mg/20 ml*
Mucinex Fast-Max, all tablet/caplet
products
325 mg
Mucinex Fast-Max, all-liquid products 650 mg/20 ml*
Robitussin Daytime Cold and Flu 325 mg
Sudafed PE Pressure and Pain
and Cough
325 mg
Tylenol Sinus/Cold, all products 325 mg
Vicks Dayquil/Nyquil,
all tablet/caplet products
325 mg
Vicks Dayquil Severe Cold & Flu Liquid 325 mg/15ml*
Vicks Nyquil Severe Cold & Flu Liquid 650 mg/30 ml*
Sleep aids
Legatrin PM 500 mg
Tylenol PM 500 mg
Unisom PM Pain 325 mg
*Recommended single dose by manufacturer. The maximum total
daily dose of acetaminophen containing products should not exceed
3000 mg (3 grams total). For further information regarding additional
OTC products, see http://www.fda.gov/Drugs/DrugSafety/Informationby-
DrugClass/ucm165107.htm
Abbreviation: HBP, high blood pressure.
Figure 1 Modified Rumack-Matthew nomogram in APAP overdose. The
modified Rumack-Matthew nomogram should only be used in patients with
one time-point APAP ingestion. Subjects with a serum APAP level above the
line are at risk for developing hepatotoxicity and should be hospitalized and
given NAC for a minimum of 24 hours. The serum APAP level should be plot-
ted in relationship to the estimated time of oral ingestion and should be
repeated 4 hours after presentation in subjects with an unreliable history. The
nomogram should not be used in ingestions that occurred> 24 hours prior to
presentation or in patients who have overdosed over several days. This figure
has been adapted from N Engl J Med.4
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liver injury should receive a full 72 hours of NAC therapy,
and those with poor prognostic indicators should be identi-
fied for early liver transplantation (LT) evaluation (Table 4).
Prognosis and Outcomes
Transplant-free survival from APAP-related ALF is signifi-
cantly higher (70%) compared to ALF from idiosyncratic
drug reactions (< 25%) or other causes of ALF (0%-50%).8
Multiple prognostic scoring systems have been evaluated to
identify the patients at increased risk of death without LT
from APAP ALF (Table 3).9 The King’s College criteria with
or without arterial lactate levels are the most commonly
used criteria to list patients for LT. In a large multicenter
prospective study of 275 APAP ALF patients, 178 (65%)
patients survived without LT, 23 (8%) patients underwent
LT, and 74 (27%) patients died.3 The Apache II (Acute
Physiology and Chronic Health Evaluation II) score yielded
higher sensitivity but slightly lower specificity than King’s
College criteria. One-year survival after LT for APAP ALF is
73%.10 For APAP hepatotoxicity patients not requiring LT,
the mean length of stay for intentional overdose patients is
4 days, and for nonintentional overdose patients it is 9
days.
Prevention of Acetaminophen Overdose
Several steps have been taken by regulatory authorities to
change the labeling and dispensing of the hundreds of pre-
scription and over-the-counter (OTC) products containing
APAP (Table 5). In 1998, the United Kingdom limited the
sale of OTC APAP to 8 grams and required blister packag-
ing of APAP products. This resulted in significant decrease
in the APAP overdose cases, number of admissions to liver
units, and number of liver transplants due to APAP over-
dose.11 In 2006, the FDA enacted changes in the labeling of
TABLE 2 Clinical Features of APAP Overdose
Detailed history Review all prescription and OTC medications.
Total dose ingested> 4 grams
Risk factors: fasting, alcohol use, concomitant
medications, polypharmacy, opioid congeners
Usually> 10 grams in 24 hours
Single timepoint ingestion: Use Rumack-Matthew
nomogram at presentation and 4 hours later
Staggered/nonintentional overdose: Serum APAP
levels may be low or undetectable. Give NAC
whenever APAP overdose suspected.
Evaluation of other
causes of acute
hepatocellular liver
injury
Hepatitis A, B, C; CMV; EBV
Pancreaticobiliary disease, vascular thrombosis,
pancreatitis, ischemia
Others etiologies based on risk factors
Establish diagnosis Serum APAP level
Urine toxicology screen
Blood alcohol level
Hep A IgM, HBsAg, anti-HBc, HCV-RNA
Liver ultrasound with Doppler
Severity assessment Serum AST, ALT, total bilirubin (most have
normal bilirubin at presentation)
Peak ALT not seen till 48-72 hours
INR
Serum creatinine, bicarbonate, phosphate level
50% of ALF patients develop AKI
Arterial pH and lactate
Factor 5 level
Encephalopathy assessment (Grade 0-4)
ICU care, if any of
these features
present
Encephalopathy grade 1 or higher
Renal failure
Metabolic acidosis
Hypotension
Transfer to liver
transplant center if
Encephalopathy grade 2 or higher
Intubated, pressors, hemodialysis
Abbreviations: AKI, acute kidney injury; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; CMV, cytomegalovirus; EBV, Epstein-
Barr virus.
TABLE 3 Treatment and Management of APAP Overdose
Initial Measures on Presentation
Within 4 hours of ingestion
Ipecac syrup, 15 ml once; repeat in 20 minutes if needed
Nasogastric lavage of pill fragments
Activated charcoal, 1 g/kg body weight (maximum dose 50 grams)
Within 16 hours of Ingestion
NAC, oral or intravenous
Oral loading: 140 mg/kg followed by 70 mg/kg every 4 hours for 17 doses
or until INR< 1.5
nausea and vomiting in 20%, mix with carbonated beverages to improve
tolerance; prochlorperazine (Compazine) 10 mg, metoclopramide (Reglan)
10 mg, or ondansetron (Zofran) 4 mg by mouth or IV; consider IV NAC if
refractory nausea and vomiting
Intravenous loading: 150 mg/kg in 250 ml dextrose 5% over 1 hour, then
50 mg/kg in 500 ml dextrose 5% over 4 hours; then 125 mg/kg in
1000 ml dextrose 5% over 19 hours; 100 mg/kg in 1000 ml dextrose 5%
over 24 hours for 2 days or until INR is less than 1.5. Contraindicated in
sulfa allergy.
IV NAC requires telemetry monitoring for arryhythmias and hypotension.
Anaphylactoid reactions with urticaria or wheezing should have the
infusion stopped and receive IM epinephrine, IV diphenhydramine,
corticosteroids and albuterol. Resumption of infusion only in a monitored
setting and consultation with local poison control center. If hypotension or
angioedema, give fluids, steroids, and epinephrine and do not resume IV
NAC (consider oral NAC with careful monitoring)
Minimum duration of NAC administration is 24 hours if no signs of liver
injury or renal failure at 24 hours and 72 hours if evidence of liver injury.
IV NAC is generally preferred in pregnant women to maximize drug levels
to fetus and also for individuals with short gut or ileus.
General Supportive Measures
Quiet and comfortable environment
Nutritional support
Monitoring of laboratory measures (every 12 hours)
Blood glucose monitoring every hour
Intravenous fluids if hypotension
Frequent screening for infection, low threshold for starting antimicrobial
agents
Avoid correction of coagulopathy except for active bleeding or invasive
procedures
Avoid nephrotoxic agents (NSAIDs, aminoglycosides)
Frequent monitoring of neurological status
Intensive Care
Urgent liver transplant evaluation
Encephalopathy grade I or II
Computed tomography of head to evaluate bleeding/cerebral edema
Avoid sedation; propofol and midazolam preferred for severe agitation
Keep head of bed> 30 degrees to avoid intracranial hypertension
Encephalopathy grade III or IV
Avoid fever; goal temperature  36C
Intubation and mechanical ventilation
Vasopressor support if persistent hypotension despite IV fluids
Renal support: CVVH preferred over hemodialysis
Invasive monitoring of intracranial pressure, treat with hyperventilation,
mannitol or hypertonic saline; barbiturate coma for refractory cases
Abbreviations: CVVH, continuous veno-venous hemofiltration; NSAID,
nonsteroidal anti-inflammatory drugs.
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all OTC products that contain APAP to include extra warn-
ings. More recently, the FDA has limited the dose of APAP in
prescription combination products to a maximum of 325 mg
per tablet and also included black-box warnings on these
products regarding their APAP content. In addition to regula-
tory actions, patient education by health care providers is
TABLE 4 Prognostic Scoring Systems Used to Identify Patients at High Risk of Mortality Without Liver Transplantation Due to APAP-Related ALF
Scoring System Key Components Sensitivity Specificity
King’s College criteria Arterial pH< 7.30 55% 93%
or
Prothrombin time> 100 plus 58% 95%
Encephalopathy grade> 2 plus
Serum creatinine> 3.4 mg/dl
Arterial lactate 3.5 mmol/l on presentation 81% 72%
or
> 3 mmol/l after fluid resuscitation 81% 77%
Modified King’s
College criteria
King College criteria plus arterial lactate> 3 mmol/l
following resuscitation
91% 71%
APACHE II Score> 15 at 24-hour postadmission 79% 97%
SOFA score Score> 8 at admission 67% 66%
MELD score MELD> 30 97% 68%
ALFSG index Coma grade, bilirubin, INR, serum phosphate, M-30
(serum marker of apoptosis)
86% 65%
Routinely used indicators
of poor prognosis
Arterial pH< 7.3 Presence of 2 or more factors associated
with poor transplant-free survivalArterial lactate> 3 mmol/l following resuscitation
Encephalopathy grade III or IV
Factor V ratio< 20%
Sensitivities and specificities stated for transplant-free survival.
Abbreviations: ALFSG, Acute Liver Failure Study Group; MELD, Model for End-Stage Liver Disease; SOFA, Sequential Organ Failure Assessment.
TABLE 5 Regulatory and Educational Measures Undertaken to Reduce the Incidence of APAP Overdose
United Kingdom
legislation, 1998 Acetaminophen sale in blister pack only
Maximum tablets in OTC packets restricted to 16 (500-mg strength)
Maximum tablets issued by pharmacist restricted to 32 (500-mg strength)
FDA, 2006 Labeling changes on all APAP containing OTC products
Black-box ‘‘liver warning’’
Increase font size and highlighting of the ingredient name ‘‘acetaminophen.’’
Warning for patients with liver disease and those that consume 2-3 alcoholic
beverages/day to consult a doctor before using the product
FDA, 2014 Prescription APAP combination products limited to no more than 325 mg acetaminophen per dosage unit
Combination product labels to include black-box warning regarding APAP content and potential for hepatotoxicity
OTC products still allowed to contain> 325 mg/dose, and many have 500-650 mg/dose (see Table 1)
Discontinued New Formulations
Brand Generic Brand Generic
Lortab Elixir Hydrocodone-acetaminophen
2.5-500 mg/5 ml oral solution
7.5-500 mg/5 ml oral solution
NAHycet Hydrocodone-acetaminophen
2.5-108 mg/5 ml oral solution
7.5-325 mg/15 ml oral solution
Lortab Hydrocodone-acetaminophen
7.5-500 mg tablet
NorcoVicodin-ES Hydrocodone-acetaminophen
7.5-325 mg tablet7.5-300 mg
tablet
Lortab Hydrocodone-acetaminophen
10-500 mg tablet
NorcoVicodin-HP Hydrocodone-acetaminophen
10-325 mg tablet10-300 mg tablet
Percocet Oxycodone-acetaminophen
7.5-500 mg tablet
Percocet Oxycodone-acetaminophen
7.5-325 mg tablet
Percocet Oxycodone-acetaminophen
10-650 mg tablet
Percocet Oxycodone-acetaminophen
10-325 mg tablet
Phrenilin Forte Butalbital-acetaminophen
50-650 mg capsule
Phrenilin Butalbital-acetaminophen
50-325 mg capsule
AGA Medicine Safety
Campaign, 2013
Emphasis on patient education regarding the safety of OTC pain medications.
A short online video at http://gutcheck.gastro.org
An infographic available online and for use in doctor’s offices.
Other educational materials for patients.
Abbreviations: ES, acetaminophen hydrocodone; HP, hydrocodone bitartrate and acetaminophen.
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extremely important. The American Gastroenterological Asso-
ciation (AGA) has launched an innovative campaign compris-
ing of a short online video (http: //gutcheck.gastro.org) and
other education materials to help raise awareness among
patients regarding OTC and prescription medications con-
taining APAP. However, a recent prospective study has dem-
onstrated the limitations of written and even verbal
instructions to patients regarding the potential for inadvertent
APAP toxicity when using multiple products.12
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